Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortization of GoodwillAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Avanos Medical (AVNS) Short-Term Debt issuances (2020 - 2024)

Avanos Medical recorded quarterly Short-Term Debt issuances of $20.0 million in Q1 2024, down 63.64% quarter-over-quarter from $55.0 million in Q3 2023.

Avanos Medical's Short-Term Debt issuances history runs 5 years deep, the most recent figure standing at $20.0 million for Q1 2024.

  • In Q1 2024, Short-Term Debt issuances changed N/A year-over-year to $20.0 million; the TTM figure through Dec 2024 stood at $20.0 million (down 63.64% YoY), while the FY2024 annual figure was $20.0 million, down 63.64% from the prior year.
  • Short-Term Debt issuances came in at $20.0 million for Q1 2024 at Avanos Medical, down from $55.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $185.0 million in Q4 2020 to a low of $20.0 million in Q3 2021.
  • A 5-year average of $71.7 million and a median of $37.5 million in 2021 frame the typical range for Short-Term Debt issuances.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 31.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -1.23 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -1.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 37.80 Mn
10 Avanos Medical 1.17 Bn 1.10 Bn 94.20 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 20.00 Mn
Mar 31, 2024 20.00 Mn
Sep 30, 2023 55.00 Mn
Sep 30, 2023 55.00 Mn
Jun 30, 2022 130.00 Mn
Jun 30, 2022 130.00 Mn
Mar 31, 2022 20.00 Mn
Mar 31, 2022 20.00 Mn
Sep 30, 2021 20.00 Mn
Sep 30, 2021 20.00 Mn
Dec 31, 2020 185.00 Mn
Dec 31, 2020 185.00 Mn